Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Jae Cheol Lee

12PUBLICATIONS
29CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyMedical biotechnology diagnostics (incl. biosensors)Physiotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

Sort by Publication Date:
|Feb 09, 2026
Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study.

Min Jee Kim, Junghee Jung, Wonjun Ji

|Sep 12, 2023
Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial.

Jiwon Kim, Chang-Min Choi, Wonjun Ji

|Jun 14, 2022
The reversible fourth-generation EGFR tyrosine kinase inhibitor OBX02-011 overcomes C797S-mediated resistance in lung cancer.

Yun Jung Choi, Da-Som Kim, Young Hoon Sung

|Jun 27, 2021
Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung.

Yoon Jung Jang, Dong-Gon Hyun, Chang-Min Choi

|Mar 22, 2021
Diagnostic yield and safety of biopsy guided by electromagnetic navigation bronchoscopy for high-risk pulmonary nodules.

Ju Hyun Oh, Chang-Min Choi, Seulgi Kim

|Dec 03, 2020
Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A.

Cheol-Kyu Park, Sung-Yong Lee, Jae Cheol Lee

Pageof 2

Frequent Collaborators

8 joint publications

Chang-Min Choi

5 joint publications

Wonjun Ji

3 joint publications

Hyeong Ryul Kim

2 joint publications

Yu Rang Park

2 joint publications

Se Jin Jang

2 joint publications

Seulgi Kim

2 joint publications

Hee Kwon

1 joint publications

Soo Hyeon Bae

1 joint publications

Eul Ju Seo

1 joint publications

Sojung Park

Frequent Collaborators

8 joint publications

Chang-Min Choi

5 joint publications

Wonjun Ji

3 joint publications

Hyeong Ryul Kim

2 joint publications

Yu Rang Park

Top Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on : Nov 22, 2021

4.6K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

8.9K
See more related videos

Top Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on : Nov 22, 2021

4.6K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

8.9K
See more related videos